Antiretroviral therapy coverage for PMTCT in Arab World
Arab World: Antiretroviral therapy coverage for PMTCT was 26.5% in 2019. ◆ Volatile
Antiretroviral therapy coverage for PMTCT in Arab World, 2000–2019
Source: UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS). Measured in % of pregnant women living with HIV.
Analysis
In 2019, antiretroviral therapy coverage for pmtct in Arab World stood at 26.5%. That is the highest value across all 19 years on record.
Compared with earlier readings it is up 9.3% on the previous year and up 269.1% over ten years.
Over the whole period, antiretroviral therapy coverage for pmtct in Arab World peaked at 26.5% in 2019 and was at its lowest, 0.0%, in 2000.
The series is highly variable year to year, so single readings are best treated with caution.
Antiretroviral therapy coverage for PMTCT in Arab World, year by year
| Year | % of pregnant women living with HIV | Change |
|---|---|---|
| 2000 | 0.0% | — |
| 2001 | 0.0% | — |
| 2002 | 0.0% | — |
| 2003 | 0.4% | +1112.3% |
| 2004 | 0.6% | +39.2% |
| 2005 | 1.3% | +126.9% |
| 2006 | 2.6% | +103.7% |
| 2007 | 3.5% | +35.6% |
| 2008 | 5.9% | +68.7% |
| 2009 | 7.2% | +21.4% |
| 2010 | 11.3% | +57.3% |
| 2011 | 11.9% | +5.4% |
| 2012 | 13.9% | +17.0% |
| 2013 | 15.8% | +13.7% |
| 2014 | 20.3% | +28.3% |
| 2015 | 20.0% | -1.4% |
| 2017 | 22.5% | +12.4% |
| 2018 | 24.3% | +7.8% |
| 2019 | 26.5% | +9.3% |
Biggest year-on-year movements
Years where Antiretroviral therapy coverage for PMTCT in Arab World changed far more than this series normally does. A large move can be a real event or a change in how the figure was measured — the source note below says who published it.
| Year | Change | From | To |
|---|---|---|---|
| 2003 | +1112.3% | 0.0% | 0.4% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 2.1% | 0.0% | 7.2% | 10 |
| 2010s | 18.5% | 11.3% | 26.5% | 9 |
Countries ranked near Arab World
More health data for Arab World
- Population ages 40-44, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 45-49, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 15-64, male, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 45-49, female, annual growth rate 3.67 % change on previous year (2025)
- Population ages 40-44, male, per capita 0.0342 units per person (2025)
- Population ages 40-44, male, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 05-09, male, annual growth rate 0.0711 % change on previous year (2025)
- Population ages 40-44, male, annual growth rate 2.95 % change on previous year (2025)
- Population ages 40-44, female, per capita 0.0298 units per person (2025)
- Population ages 35-39, female, per capita 0.0338 units per person (2025)
Frequently asked questions
- What is antiretroviral therapy coverage for pmtct in Arab World?
- Antiretroviral therapy coverage for pmtct in Arab World was 26.5% in 2019, according to UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS).
- What is the highest antiretroviral therapy coverage for pmtct recorded in Arab World?
- The highest recorded value was 26.5% in 2019.
- What is the lowest antiretroviral therapy coverage for pmtct recorded in Arab World?
- The lowest recorded value was 0.0% in 2000.
- How does Arab World rank for antiretroviral therapy coverage for pmtct?
- Arab World ranks 12th out of 15 groups with data for 2019.
- Is antiretroviral therapy coverage for pmtct rising or falling in Arab World?
- Over the last ten years it is up 269.1%. The long-run trend across the full record is volatile.
- Where does this Arab World data come from?
- The figures come from UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS), published as part of Antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 19 observations, free to reuse under CC BY 4.0 (World Bank Open Data).
About this data
Percentage of pregnant women with HIV who receive antiretroviral medicine for prevention of mother-to-child transmission (PMTCT).